SMS Pharmaceuticals Limited (SMSPHARMA) Price & Analysis

Compare

1 Followers

SMSPHARMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range₹175.00 - ₹398.00

Previous CloseN/A

Volume71.57K

Average Volume (3M)5.23K

Market Cap

₹20.50B

Enterprise Value₹21.55B

Total Cash (Recent Filing)₹90.66M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)27.1

Beta1.26

Next Earnings

Nov 07, 2025

EPS EstimateN/A

Next Dividend Ex-Date

Sep 22, 2025

Dividend Yield0.17%

Share Statistics

EPS (TTM)2.31

Shares Outstanding88,652,030

10 Day Avg. Volume3,055

30 Day Avg. Volume5,228

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹241.00

Price Target Upside6.64% Upside

Rating ConsensusHold

Number of Analyst Covering1

SMS Pharmaceuticals Limited News

SMS Pharmaceuticals Reports Strong Q1 Financial Performance

SMS Pharmaceuticals Limited ( ($IN:SMSPHARMA) ) has issued an announcement. SMS Pharmaceuticals Limited reported a strong financial performance...

19d ago

SMS Pharmaceuticals Releases Q1 FY26 Investor Presentation

An announcement from SMS Pharmaceuticals Limited ( ($IN:SMSPHARMA) ) is now available. SMS Pharmaceuticals Limited has released its...

19d ago

SMS Pharmaceuticals Transfers Shares to IEPF for Unclaimed Dividends

An announcement from SMS Pharmaceuticals Limited ( ($IN:SMSPHARMA) ) is now available. SMS Pharmaceuticals Limited announced the transfer...

2M ago

SMS Pharmaceuticals Ensures Compliance with SEBI Regulations

An announcement from SMS Pharmaceuticals Limited ( ($IN:SMSPHARMA) ) is now available. SMS Pharmaceuticals Limited has announced that...

8M ago

SMSPHARMA FAQ

What was SMS Pharmaceuticals Limited’s price range in the past 12 months?

SMS Pharmaceuticals Limited lowest stock price was ₹175.00 and its highest was ₹398.00 in the past 12 months.

What is SMS Pharmaceuticals Limited’s market cap?

SMS Pharmaceuticals Limited’s market cap is ₹20.50B.

When is SMS Pharmaceuticals Limited’s upcoming earnings report date?

SMS Pharmaceuticals Limited’s upcoming earnings report date is Nov 07, 2025 which is in 70 days.

How were SMS Pharmaceuticals Limited’s earnings last quarter?

SMS Pharmaceuticals Limited released its earnings results on Aug 09, 2025. The company reported ₹2.311 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.311.

Is SMS Pharmaceuticals Limited overvalued?

According to Wall Street analysts SMS Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SMS Pharmaceuticals Limited pay dividends?

SMS Pharmaceuticals Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of 0.17%. See more information on SMS Pharmaceuticals Limited dividends here

What is SMS Pharmaceuticals Limited’s EPS estimate?

SMS Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SMS Pharmaceuticals Limited have?

SMS Pharmaceuticals Limited has 88,652,030 shares outstanding.

What happened to SMS Pharmaceuticals Limited’s price movement after its last earnings report?

SMS Pharmaceuticals Limited reported an EPS of ₹2.311 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.746%.

Which hedge fund is a major shareholder of SMS Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:SMSPHARMA

Company Description

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral APIs. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.

SMS Pharmaceuticals Limited (SMSPHARMA) Earnings & Revenues

Historic Earnings Reports

SMSPHARMA Stock 12 Month Forecast

Average Price Target

₹241.00

▲(6.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"190":"₹190","375":"₹375","236.25":"₹236.3","282.5":"₹282.5","328.75":"₹328.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":241,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹241.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":241,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹241.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":241,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹241.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[190,236.25,282.5,328.75,375],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.65,229.6,230.55,231.5,232.45000000000002,233.4,234.35,235.3,236.25,237.2,238.15,239.1,240.05,{"y":241,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.65,229.6,230.55,231.5,232.45000000000002,233.4,234.35,235.3,236.25,237.2,238.15,239.1,240.05,{"y":241,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,228.65,229.6,230.55,231.5,232.45000000000002,233.4,234.35,235.3,236.25,237.2,238.15,239.1,240.05,{"y":241,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":333.74,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":374.75,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":294.6,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":261.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":258.05,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":202.35,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":191.35,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":218.6,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":235.15,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":259.1,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":248.05,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":248.05,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":228.65,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >